GlassScriptPhysician profile
Byron S Thomas
NPI 1952564502
$1,800.84
in general payments reported to CMS, 2019-2025
29 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $132 · 2021: $30.02 · 2022: $184 · 2023: $532 · 2024: $397 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,235.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $307.21 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Grifols USA, LLC | $174.62 | 2020-2025 | Prolastin-C Liquid |
| Novo Nordisk INC | $169.15 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $163.72 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $106.02 | 2019-2023 | Jardiance, Mounjaro |
| Amgen INC. | $102.59 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $82.53 | 2019-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.48 | 2022-2023 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $66.72 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $57.77 | 2024-2025 | Voquezna |
| Supernus Pharmaceuticals, INC. | $56.04 | 2020 | |
| Pfizer INC. | $48.07 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.56 | 2022 | |
| Amarin Pharma, INC. | $43.11 | 2019 | |
| Exact Sciences Corporation | $37.65 | 2024-2025 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $36.31 | 2022-2023 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $32.55 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $22.74 | 2024 | Abilify Maintena, Rexulti |
| Sunovion Pharmaceuticals INC. | $18.54 | 2022 | |
| Kyowa Kirin, INC. | $17.84 | 2025 | |
| Gilead Sciences, INC. | $16.46 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.94 | 2025 | Caplyta |
| Melinta Therapeutics, LLC | $15.75 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.15 | 2023 | Xifaxan |
| Ardelyx, INC. | $15.13 | 2024 | Ibsrela |
| Astellas Pharma US INC | $14.78 | 2023 | Veozah |
| Merck Sharp & Dohme LLC | $14.38 | 2025 | Zerbaxa |
| Sanofi-Aventis U.S. LLC | $13.83 | 2019 | |
| Allergan, INC. | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Byron Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.